Last reviewed · How we verify
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.
Details
| Lead sponsor | Peking University |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 252 |
| Start date | 2022-08-15 |
| Completion | 2025-12 |
Conditions
- Outpatients / Inpatients With Depression
Interventions
- Escitalopram
- Escitalopram+Aripiprazole
- Escitalopram+omega-3 PUFAs
- Escitalopram+Aripiprazole+omega-3 PUFAs
Primary outcomes
- 17-item Hamilton depression rating scale (HAMD-17) value — Day 0 to Day 56
The value of 17-item Hamilton depression rating scale (HAMD-17) total score treatment compared to that at the baseline. The maximum score of HAMD-17 is 51 and the minimum is 0. Higher scores mean a worse outcome. - Anhedonia level-Dimensional Anhedonia Rating Scale (DARS) — Day 0 to Day 56
The outcome is measured by Dimensional Anhedonia Rating Scale (DARS) total score. The maximum score of DARS total score is 68 and the minimum is 0. Higher scores mean a better outcome.
Countries
China